

(12) STANDARD PATENT
(19) AUSTRALIAN PATENT OFFICE

(11) Application No. **AU 2011276479 B2**

(54) Title
Methods and compositions for enhancing stem cell mobilization

(51) International Patent Classification(s)
A01N 43/04 (2006.01) **A61K 31/715** (2006.01)
A61K 31/70 (2006.01) **A61K 36/815** (2006.01)

(21) Application No: **2011276479** (22) Date of Filing: **2011.06.28**

(87) WIPO No: **WO12/006100**

(30) Priority Data

(31) Number	(32) Date	(33) Country
61/359,288	2010.06.28	US
61/427,023	2010.12.23	US

(43) Publication Date: **2012.01.12**

(44) Accepted Journal Date: **2015.06.25**

(71) Applicant(s)
Stemtech International, Inc.

(72) Inventor(s)
Drapeau, Christian;Jensen, Gitte S.

(74) Agent / Attorney
Freehills Patent Attorneys, Level 43 101 Collins ST, Melbourne, VIC, 3000

(56) Related Art
D7 : JP 2003-259844 A (ARUGA KK MINATO PHARMACEUTICAL CO LTD) 16 September 2003
D6 : JP 2009-221133 A (DAIICHI YAKUHIN KOGYO KK) 01 October 2009
D9 : KR 20080007698 A (JEON HONG IL) 23 January 2008
D8 : JP 2003-135028 A (SOCIAL EXCELLENT COMMUNITY KK) 13 May 2003
D10 : KISS ET AL:"Enhancement of organ regeneration in animal models by a stem cell stimulating plant mixture". Journal of Medicinal Food, June 3 2010 (available online 21 April 2010), vol. 13, no. 3, pages 599-604.
D3 : US 2010/0144667 A1 (SHAKLEE ET AL) 10 June 2010
D5 : US 2007/0003669 A1 (KEARL ET AL) 04 January 2007
D2 : US 2007/0190023 A1 (BATTISTA ET AL) 16 August 2007
D4 : Zradical juice [retrieved on 3 June 2014] Retrieved from internet <URL: <http://escapeyoung.wordpress.com/2009/11/05/talking-about-zradical-juice-has-acai-berry-mangosteenother-healthy-ingredients/> published on Nov 5 2009
D1 : IRHIMEH ET AL: "Fucoïdan ingestion increases the expression of CXCR4 on human CD34+ cells". Experimental Hematology, 2007, vol. 35, no. 6, pages 989-994.

(19) World Intellectual Property Organization
International Bureau



(10) International Publication Number
WO 2012/006100 A3

(43) International Publication Date
12 January 2012 (12.01.2012)

- (51) **International Patent Classification:**
A01N 43/04 (2006.01) A61K 31/715 (2006.01)
A61K 31/70 (2006.01)
- (21) **International Application Number:**
PCT/US2011/042211
- (22) **International Filing Date:**
28 June 2011 (28.06.2011)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
61/359,288 28 June 2010 (28.06.2010) US
61/427,023 23 December 2010 (23.12.2010) US
- (71) **Applicant (for all designated States except US):**
STEMTECH INTERNATIONAL, INC. [US/US]; 1011
Calle Amanecer, San Clemente, California 92673 (US).
- (72) **Inventors; and**
- (75) **Inventors/Applicants (for US only):** **DRAPEAU, Christian** [US/US]; 1011 Calle Amanecer, San Clemente, California 92673 (US). **JENSEN, Gitte, S.** [DK/CA]; 12 Denby Road, Port Dover, Ontario N0A 1N4 (CA).


- (74) **Agents:** **CHEN, Stephen** et al.; Davis Wright Tremaine LLP, 865 South Figueroa Street, Suite 2400, Los Angeles, California 90017 (US).
- (81) **Designated States (unless otherwise indicated, for every kind of national protection available):** AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
- (84) **Designated States (unless otherwise indicated, for every kind of regional protection available):** ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— with international search report (Art. 21(3))

[Continued on next page]

(54) **Title:** METHODS AND COMPOSITIONS FOR ENHANCING STEM CELL MOBILIZATION

Figure 1.



(57) **Abstract:** A method of using fucoidan to enhance stem cell mobilization in a subject, including hematopoietic stem cells (HSCs) and bone marrow stem cells (BMSCs) is provided. In the method, a blended composition of fruits, mushrooms, microorganisms, maternal fluids, and extracts thereof are used to promote trafficking of stem cells, resulting in migration of the stem cells to specific sites of maintenance and repair within tissues and/or organs. The method also involves the use of fucoidan obtained from particular algae species to support release and circulation of HSCs, as demonstrated by significantly increase circulation of HSCs in the peripheral blood. Increased circulation of HSCs and/or BMSCs and migration towards sites of maintenance and the natural regeneration mechanisms in the body. Further provided is a dosing regimen for the administration of fucoidan and a method of enhancing release and circulation of stem cells.



WO 2012/006100 A3



— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(88) Date of publication of the international search report:
15 March 2012

METHODS AND COMPOSITIONS FOR ENHANCING STEM CELL MOBILIZATION

FIELD OF THE INVENTION

The present invention relates to methods and compositions for enhancing the mobilization of stem cells.

BACKGROUND OF THE INVENTION

Reference to any prior art in the specification is not, and should not be taken as, an acknowledgment or any form of suggestion that this prior art forms part of the common general knowledge in Australia or any other jurisdiction or that this prior art could reasonably be expected to be ascertained, understood and regarded as relevant by a person skilled in the art.

All publications herein are incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference. The following description includes information that may be useful in understanding the present invention. It is not an admission that any of the information provided herein is prior art or relevant to the presently claimed invention, or that any publication specifically or implicitly referenced is prior art.

Stem cells (SC) are defined as cells with the unique capacity to self-replicate throughout the entire life of an organism and to differentiate into various cell types of the body. Two well-known types of stem cells are embryonic stem cells and adult stem cells. Embryonic stem cells (ESCs) are extracted from 5-10 day old embryos called blastulas. Once isolated, ESCs can be grown in vitro and led to differentiate into various types of tissue cell (such as heart cells, liver cells, nervous cells, and kidney cells), after which they can be injected in specific tissues in order to regenerate the tissue.

Adult stem cells (ASCs) are undifferentiated or primitive cells that can self-renew and differentiate into specialized cells of various tissues and are found in any living organism after birth. ASCs have been isolated from various tissues such as the liver (oval cells) (Wang et al., 2003), the intestine (intestinal crypt stem cells) (Barker et al., 2008), muscles (satellite cells) (Kuang et al., 2008), the brain (neural stem cells) (Revishchin et al., 2008), and recently the pancreas (nestin positive pancreatic stem

cells) (Burke et al., 2007). Umbilical cord stem cells and placental stem cells are considered ASCs.

The role of ASCs found in tissues (tissue stem cells) is to maintain and repair the tissue in which they are found, although recent studies have reported that ASCs from one tissue may have the ability to develop into cell types characteristic of other

2011276479 23 May 2014

tissues. For example, oval cells in the liver were shown in vitro to have the ability to become insulin-producing pancreatic cells. (Yang et al. 2002) Nevertheless, the general view is that local stem cells are primarily involved in minor repair of the tissue in which they reside. In the case of significant injury or degeneration, the number of new tissue cells found in healing tissue far exceeds the capacity of local stem cells to duplicate and differentiate, suggesting that stem cells coming from other sites must be involved in the process of repair.

Although many tissues contain their own specific population of tissue stem cells, certain ASCs of key interest are those primarily found in the bone marrow and blood, Tissue stem cells are traditionally believed to be limited in their ability to differentiate into other tissues, however bone marrow stem cells (BMSC) were recently shown to have significant capability to become cells of other tissues.

It is difficult to freeze these processes in time to extract a cohesive, comprehensive portrait of regenerative mechanisms in the body. Nonetheless, enough information is available to affirm that different stem cells in the body, whether BMSCs, HSCs, marrow stromal cells (MSCs), multipotent adult progenitor cells (MAPCs), very small embryonic-like stem cells (VSEL), epiblast-like stem cell (ELSC) or blastomere-like stem cell (BLSC), constitute a broad component of the body's natural healing system. Since stem cells are capable of differentiating into a broad variety of cell types, they play an important role in the healing and regenerative processes of various tissues and organs. Bone marrow stem cells, including marrow stromal cells (MSCs), are released from tissues of origin, and circulate in a subject's circulatory or immune system to migrate into various organs and tissues to become mature, terminally differentiated cells. Therefore, enhancement of stem cell trafficking (i.e., release, circulation, homing and/or migration) can amplify these physiological processes and provide potential therapies for various pathologies. There are compositions and methods that utilize stem cell mobilization as a therapeutic approach. However, existing methods of promoting stem cell mobilization suffer from significant drawbacks, including poor kinetic performance, high cost, inconvenient methods of administration and unwanted side effects. One leading approach, injection of granulocyte colony-stimulating factor (G-CSF) or recombinant forms thereof, requires days to achieve peak circulating HSC numbers. The opposite problem exists with administration of interleukin-8 (IL-8), which acts only within minutes and has a short-lived effect on elevating circulating

HSC levels in the bloodstream. (Frenette et al., 2000; Jensen et al., 2007) G-CSF and a different molecule, CXCR4 antagonist AMD3100, can have significant side effects, including hemorrhaging, rupturing of the spleen, bloody sputum, bone disorders, among others. Thus, there is a need in the art for an effective and convenient method for delivering stem cell mobilization agents to human subjects, to obtain positive clinical benefits without side effects and at a reduced cost.

Accordingly, the inventive compositions and methods disclosed herein enhance the release, circulation, homing and/or migration of stem cells within the body to promote healing and treatment of damaged tissues, as well as aid in the regeneration of tissues that suffer from some level of cellular loss, for greater vitality and reduced incidence of disease.

SUMMARY OF THE INVENTION

The following embodiments and aspects thereof are described and illustrated in conjunction with compositions and methods which are meant to be exemplary and illustrative, not limiting in scope. In one embodiment, the invention includes a method of increasing stem cell mobilization in a subject, comprising: providing a mobilization agent capable of increasing stem cell mobilization, and administering a quantity of the mobilization agent to the subject in an amount sufficient to increase stem cell mobilization in the subject. In another embodiment, the mobilization agent is a composition comprising one or more of the following components selected from the group consisting of: *Lycium barbarum* or extracts thereof, colostrum or extracts thereof, spirulina or extracts thereof, fucoidan, *Hericium erinaceus* or extracts thereof, *Ganoderma Lucidum* or extracts thereof, and/or *Cordyceps Sinensis* or extracts thereof. In another embodiment, the mobilization agent is fucoidan. In another embodiment, the fucoidan is extracted from *Undaria pinnatifida*. In another embodiment, the quantity of the fucoidan is 250 mg. In another embodiment, the stem cell is a bone marrow-derived stem cell (BMSC). In another embodiment, the stem cell is a hematopoietic stem cell (HSC). In another embodiment, administering the quantity comprises oral administration. In another embodiment, the oral administration comprises use of a capsule or a pill.

Another embodiment of the present invention provides a method, comprising: providing 250 mg of a fucoidan capable of increasing stem cell mobilization, and orally administering the fucoidan to a subject once a day. In another embodiment,

the stem cell is a bone marrow-derived stem cell (BMSC). In another embodiment, the stem cell is a hematopoietic stem cell (HSC). In another embodiment, the fucoidan is extracted from *Undaria pinnatifida*.

Another embodiment of the present invention provides a pharmaceutical composition comprising: one or more of the following components selected from the group consisting of: *Lycium barbarum* or extracts thereof, colostrum or extracts thereof, spirulina or extracts thereof, fucoidan, *Hericium erinaceus* or extracts thereof, *Ganoderma Lucidum* or extracts thereof, and/or *Cordyceps Sinensis* or extracts thereof, and a pharmaceutically acceptable carrier. In another embodiment, the quantity of *Lycium barbarum* or extracts thereof, comprises 500-2000 mg in a single dose. In another embodiment, the quantity of colostrum or extracts thereof, comprises 75-300 mg in a single dose. In another embodiment, the quantity of spirulina or extracts thereof, comprises 75-300 mg in a single dose. In another embodiment, the quantity of *Hericium erinaceus* or extracts thereof, *Ganoderma Lucidum* or extracts thereof, and/or *Cordyceps Sinensis* or extracts thereof comprises 83-1000 mg in a single dose.

BRIEF DESCRIPTION OF THE FIGURES

Exemplary embodiments are illustrated in referenced figures. It is intended that the embodiments and figures disclosed herein are to be considered illustrative rather than restrictive.

Figure 1 depicts mobilization and migration of endogenous stem cells in accordance with various embodiments of the present invention. Under normal physiological conditions or in response to disease or injury, hematopoietic stem cells mobilize from compartments such as bone **(A)** and circulate into the bloodstream **(B)**, migrate towards tissues to promote repair and regeneration in different parts of the body **(C)**.

Figure 2 shows a schematic illustration of the steps involved in the migration of a stem cell, underscoring the role of CXCR4, in accordance with an embodiment of the present invention.

Figure 3 provides graphs illustrating a typical time course of stem cell migration in the human body after consumption of **(A)** whole *Lycium Barbarum* (LB) fruit and **(B)** colostrum (Col), in accordance with various embodiments of the present invention. For both products, the thin lines show individual responses. For LB, the

thick dotted line is the average response while the thick line shows the time course of the response with the average peak response at 45 minutes. For Col, all participants peaked at 60 minutes, so the thick lines show the average time course of the response.

5 **Figure 4** provides a graph illustrating a typical time course of stem cell migration in the human body after consumption of **(A)** a polysaccharide rich fraction of mushroom (*Cordyceps sinensis*, *Ganoderma lucidum*, *Hericium erinaceus*), and **(B)** spirulina or an extract thereof, in accordance with an embodiment of the present invention.

10 **Figures 5A, 5B and 5C** are flow cytometry profiles of blood samples showing the proportions of CD34+ lymphocytes from the peripheral blood of a human volunteer after ingestion of *L. Barbarum*, colostrum and mushroom polysaccharides, respectively, in accordance with an embodiment of the present invention. The X axis displays fluorescence intensity of the stem cell marker. The M1 marker indicates
15 events showing positivity for the stem cell marker CD34.

Figure 6 is a graph illustrating the expression of CXCR4 molecules on the surface of CD34+ circulating stem cells before and after consumption of LB, Col, and mushroom polysaccharides, in accordance with an embodiment of the present invention.

20 **Figure 7** provides a graph illustrating a typical time course of stem cell migration in the human body after consumption of *Lycium Barbarum*, colostrum, spirulina and a polysaccharide rich fraction of mushroom (*Cordyceps sinensis*, *Ganoderma lucidum*, *Hericium erinaceus*), in accordance with an embodiment of the present invention.

25 **Figure 8** depicts changes in circulating CD34+ hematopoietic stem cells in human volunteers following oral administration of fucoidan extracted from *Undaria pinnatifida* in accordance with various embodiments of the present invention. Baseline levels of peripheral blood stem cells were quantified in volunteers. Volunteers then ingested 250 mg of fucoidan extracted from *Undaria pinnatifida*.
30 The levels of stem cells were subsequently measured at 45, 90 and 180 minutes. The number of circulating stem cells increased on average by 17%, 23% ($P < 0.02$) and 32% ($P < 0.02$), respectively.

Figure 9 depicts the results of consuming fucoidan from algae species, *Chordaria cladosiphon* in accordance with various embodiments of the present

invention. Consumption of 250 mg of fucoidan from *Chordaria cladosiphon* gave an average decrease in the number of circulating stem cells under the same conditions.

DETAILED DESCRIPTION OF THE INVENTION

5 All references cited herein are incorporated by reference in their entirety as though fully set forth. Unless defined otherwise, technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Singleton *et al.*, *Dictionary of Microbiology and Molecular Biology 3rd ed.*, J. Wiley & Sons (New York, NY 2001); March,
10 *Advanced Organic Chemistry Reactions, Mechanisms and Structure 5th ed.*, J. Wiley & Sons (New York, NY 2001); and Sambrook and Russell, *Molecular Cloning: A Laboratory Manual 3rd ed.*, Cold Spring Harbor Laboratory Press (Cold Spring Harbor, NY 2001), *Remington's Pharmaceutical Sciences*, by E. W. Martin, Mack Publishing Co., Easton, Pa., 15th Edition (1975), describes compositions and
15 formulations suitable for pharmaceutical delivery of the inventive compositions described herein provide one skilled in the art with a general guide to many of the terms used in the present application.

One skilled in the art will recognize many methods and materials similar or equivalent to those described herein, which could be used in the practice of the
20 present invention. Indeed, the present invention is in no way limited to the methods described herein. For purposes of the present invention, the following terms are defined below.

"Administering" and/or "administer" as used herein refer to any route for
25 delivering a pharmaceutical composition to a patient. Routes of delivery may include non-invasive peroral (through the mouth), topical (skin), transmucosal (nasal, buccal/sublingual, vaginal, ocular and rectal) and inhalation routes, as well as parenteral routes, and other methods known in the art. Parenteral refers to a route of delivery that is generally associated with injection, including intraorbital, infusion,
30 intraarterial, intracarotid, intracapsular, intracardiac, intradermal, intramuscular, intraperitoneal, intrapulmonary, intraspinal, intrasternal, intrathecal, intrauterine, intravenous, subarachnoid, subcapsular, subcutaneous, transmucosal, or transtracheal. Via the parenteral route, the compositions may be in the form of solutions or suspensions for infusion or for injection, or as lyophilized powders.

As used herein, except where the context requires otherwise the term 'comprise' and variations of the term, such as 'comprising', 'comprises' and 'comprised', are not intended to exclude other additives, components, integers or steps.

"Circulatory system" as used herein refers to the mechanisms for moving blood and blood components throughout the body of a subject, including the vascular and lymph systems. The mechanisms of the circulatory system include, but are not limited to, the heart, blood vessels (arteries, veins, and capillaries), and lymph vessels.

"Colostrum" as used herein refers to a fluid secreted by the mammary glands of female mammals during the first few days of lactation, containing various nutrients and protease inhibitors that keep it from being destroyed by the processes of digestion. Humans produce relatively small amounts of colostrum in the first two days after giving birth, but cows produce about nine gallons of colostrum. Colostrum contains concentrated levels of important immune modulators, including Transfer Factor, PRP, IGF-1, n-acetyl neuraminic acid, GMP, nucleic acid and defensins. Colostrum extracts have been shown to activate phagocytosis by monocytes and increase the reactive oxygen burst in polymorph nucleated cells. Colostrum was also shown to trigger natural killer (NK) cell activation and also trigger the secretion of anti-inflammatory cytokines in in vitro cell-based assays. References herein to colostrum also include derivatives and artificial substitutes thereof.

20 "Component of *Lycium Barbarum*" as used herein refers to any fraction, extract, or isolated or purified molecule from *Lycium Barbarum*. For example, the component is a protein or nucleic acid or a polysaccharide, a phytochemical, or a fraction of *Lycium Barbarum*. Thus, in certain embodiments of the invention, components of *Lycium Barbarum* are obtained by disrupting *Lycium Barbarum*, adding an inorganic or organic
25 solvent, and collecting fractions. Specific, non-limiting examples of fractions are isolated using high performance liquid chromatography, thin layer chromatography, or distillation. Fractionation may be based on the molecular weight or the hydrophobicity of the components of *Lycium Barbarum*.

30 "Differentiation" as used herein refers to the process by which cells become more specialized to perform biological functions. For example, hematopoietic stem cells, hematopoietic progenitors and/or stem cells may change from multipotent stem cells

into cells committed to a specific lineage and/or cells having characteristic functions, such as mature somatic cells. Differentiation is a property that is often totally or partially lost by cells that have undergone malignant transformation.

“Enhancement,” “enhance” or “enhancing” as used herein refers to an improvement in the performance of or other physiologically beneficial increase in a particular parameter of a cell or organism. At times, enhancement of a phenomenon is quantified as a decrease in the measurements of a specific parameter. For example, migration of stem cells may be measured as a reduction in the number of stem cells circulating in the circulatory system, but this nonetheless may represent an enhancement in the migration of these cells to areas of the body where they may perform or facilitate a beneficial physiologic result, including, but not limited to, differentiating into cells that replace or correct lost or damaged function. In one embodiment, enhancement refers to a 15%, 20%, 30% or greater than 50% reduction in the number of circulating stem cells. In one specific, non-limiting example, enhancement of stem cell migration may result in or be measured by a decrease in a population of the cells of a non-hematopoietic lineage, such as a 15%, 20%, 30%, 50%, 75% or greater decrease in the population of cells or the response of the population of cells. In one embodiment, an enhanced parameter is the trafficking of stem cells. In one embodiment, the enhanced parameter is the release of stem cells from a tissue of origin. In one embodiment, an enhanced parameter is the migration of stem cells. In another embodiment, the parameter is the differentiation of stem cells. In yet another embodiment, the parameter is the homing of stem cells.

“Fucoidan” as used herein describes sulfated fucans obtained from algae. Fucoidan has been obtained from a broad range of Algae species as provided in the following non-exhaustive list: *Cladosiphon okamuranus*, *Chordaria flagelliformis*, *Ch. Gracilis*, *Saundersella simplex*, *Desmaestia intermedia*, *Dictyosiphon foeniculaceus*, *Dictyota dichotoma*, *Padina pavonica*, *Spatoglossum schroederi*, *Adernocystis utricularis*, *Pylayella littoralis*, *Ascophyllum nodosum*, *Bifurcaria bifurcata*, *Fucus. Visiculosus*, *F. spiralis*, *F. serratus*, *F. evaescens*, *Himanthalia lorea*, *Hizikia fusiforme*, *Pelvetia canaliculata*, *P. wrightii*, *Sargassum stenophyllum*, *S. honeri*, *S. Khellmanium*, *S. muticum*, *Alaria fistulosa*, *A. marginata*, *Arthrothammus bifidus*, *Chorda film*, *Ecklonia kurome*, *E. cava*, *Eisenia bicyclis*, *Laminaria angustata*, *L. brasiliensis*, *L. cloustoni*, *L. digitata*, *L. japonica*, *L. religiosia*, *L. saccharina*, *Macrocystis integrifolia*, *M. pyrifera*, *Nereocystis luetkeana*, *Undaria pinnatifida*, *Petalonia fascia*, *Scytosiphon lomentaria*. Substantial pharmaceutical research has been done on fucoidan, focusing primarily on two distinct forms: F-fucoidan, which is

>95% composed of sulfated esters of fucose, and U-fucoidan, which is approximately 20% glucuronic acid, each of which is included in the term "fucoidan" as used herein. Depending on the source of the fucoidan, fucoidan can serve as a releasing agent in certain embodiments, while in other embodiments, fucoidan can serve as a migration agent.

"Hematopoiesis" as used herein refers to the formation and development of blood cells. Prenatally, hematopoiesis occurs in the yolk sack, then liver, and eventually the bone marrow. In normal adults, it occurs primarily in bone marrow and lymphatic tissues. All blood cells develop from pluripotent stem cells, which are committed to three, two, or one hematopoietic differentiation pathways. This includes the production of hematopoietic cells including B-cells, T-cells, cells of the monocyte macrophage lineage, and red blood cells.

"Hematopoietic agent" as used herein refers to a compound, antibody, nucleic acid molecule, protein, cell or other molecule that affects hematopoiesis. A molecular agent can be a naturally-occurring molecule or a synthetic molecule. In some instances, the agent affects the growth, proliferation, maturation, migration or differentiation or release of hematopoietic cells. In various embodiments, the agent is *Lycium Barbarum*, or an extract or component of *Lycium Barbarum*.

"Hematopoietic stem cells" as used in the present invention means multipotent stem cells that are capable of eventually differentiating into all blood cells including, erythrocytes, leukocytes, megakaryocytes, and platelets. This may involve an intermediate stage of differentiation into progenitor cells or blast cells. The term "hematopoietic progenitors", "progenitor cells" or "blast cells" are used interchangeably in the present invention and describe maturing HSCs with reduced differentiation potential, but are still capable of maturing into different cells of a specific lineage, such as myeloid or lymphoid lineage. "Hematopoietic progenitors" include erythroid burst forming units, granulocyte, erythroid, macrophage, megakaryocyte colony forming units, granulocyte, erythroid, macrophage, and granulocyte macrophage colony-forming units.

"Homing" as used herein refers to the process of a cell migrating from the circulatory system into a tissue or organ. In some instances, homing is accomplished via tissue-specific adhesion molecules and adhesion processes. Homing may refer to the migration back to the bone marrow.

“Immunologically normal” as used herein refers to a subject that displays immune system characteristics typical for the species to which the individual belongs. These typical characteristics include, among others, functioning B-cells and T-cells as well as structural cell components, called cell surface antigens, which
5 act as the immunologic signature for a particular organism.

“Immunologically compromised” as used herein refers to a subject having a genotypic or a phenotypic immunodeficiency. A genotypically-immunodeficient subject has a genetic defect that results in an inability to generate either humoral or cell-mediated responses. A specific, non-limiting example of a genotypically
10 immunodeficient subject is a genotypically immunodeficient mouse, such as a SCID mouse or a bg/nu/xid mouse. A "phenotypically-immunodeficient subject" is a subject, which is genetically capable of generating an immune response, which has been phenotypically altered such that no response is seen. In one specific, non-limiting example, a phenotypically-immunodeficient recipient has been irradiated. In
15 another specific, non-limiting example, a phenotypically-immunodeficient subject has been treated with chemotherapy. In yet another specific, non-limiting example, the phenotypically-immunodeficient subject has suffered a bacterial or viral infection, such as the human immunodeficiency virus (HIV) or simian immunodeficiency virus (SIV).

“Isolated biological component” (such as a nucleic acid molecule, polypeptide, polysaccharide or other biological molecule) as used herein refers to a biological component that has been substantially separated or purified away from other biological components in which the component naturally occurs. Nucleic acids and proteins may be isolated by standard purification methods, recombinant expression
20 in a host cell, or chemically synthesized.

“*Lycium Barbarum*” or “*L. Barbarum*” as used herein refers to a small bright orange-red, ellipsoid berry or fruit grown. One exemplary source is in the north of China, primarily in the Ningxia Hui Autonomous Region. It is sometimes referred to as goji berry or wolfberry. *L. Barbarum* belongs to the Solanaceae family, the
30 nightshade family that includes hundreds of plant foods like potato, tomato, eggplant, and peppers (paprika).

“Lymphoproliferation” as used herein refers to an increase in the production of lymphocytes.

“Modulation” or “modulates” or “modulating” as used herein refers to upregulation (i.e., activation or stimulation), down regulation (i.e., inhibition or suppression) of a response or the two in combination or apart.

“Migration” as used herein refers to the central process for movement of cells
5 in the development and maintenance of multicellular organisms. Cells often migrate in response to, and towards, specific external signals, commonly referred to as chemotaxis. Migration includes the process of a cell moving from the circulatory system into a tissue or organ. More specifically, circulating stem cells are tethered to the surface of capillary endothelium via expression of adhesion molecules of cell
10 surfaces, resulting in cytoskeletal changes in both endothelium and stem cells, and allowing movement through the capillary wall en route to a tissue and/or organ site. In some instances, homing is accomplished via tissue-specific adhesion molecules and adhesion processes.

“Migration agent” as used herein are mobilization agents capable of
15 promoting the process of a cell moving from the circulatory system into a tissue or organ. Migration of stem cells may be demonstrated, for example, by a decrease in circulating stem cells in the circulatory or immune system, or by the expression of surface markers and/or adhesion molecules on cell surfaces, which relate to homing, tethering, and/or extravasation of circulating stem cells to the surface of vessels such
20 as capillary endothelium. Examples of migration agents include isolated or purified components extracted from *Lycium Barbarum*, including a polysaccharide-rich fraction (fraction A) of *Lycium Barbarum* extract, colostrum, including a protein-rich fraction (fraction B) of colostrum extract, fucoidan, including an isolated component or compound extracted from an algae, such as a compound found in a
25 polysaccharide -rich fraction (fraction C) of algae extracts, including *Chordaria cladosiphon*, or other algae, or extracts thereof, mushrooms, including an isolated component or compound extracted from a mushroom, such as a compound found in a polysaccharide -rich fraction (fraction D) of mushroom extracts, including
Cordyceps sinensis or an extract thereof, *Ganoderma lucidum* or an extract thereof,
30 *Hericium erinaceus* or an extract thereof, spirulina, including *Arthrospira platensis*, *Arthrospira maxima*, or extracts thereof. In different embodiments, this agent affects the migration of stem cells, such as CD34^{high} (CD34+) cells. In one embodiment, the migration agent decreases the number of bone marrow-derived stem cells and/or hematopoietic stem cells circulating in the peripheral blood. In another embodiment,

the migration agent relates to enhanced expression of CXCR4 on circulating stem cells.

“Mushroom polysaccharides” as used herein refers to glucans found mainly in various species of mushrooms such as *Cordyceps sinensis*, *Hericium erinaceus*,
5 and *Ganoderma lucidum*. This also includes the numerous bioactive polysaccharides or polysaccharide-protein complexes from medicinal mushrooms that may enhance innate and cell-mediated immune responses, and exhibit antitumor activities in animals and humans.

“Pharmaceutically acceptable carriers” as used herein refer to conventional
10 pharmaceutically acceptable carriers useful in this invention.

“Polysaccharide” as used herein refers to a polymer of more than about ten monosaccharide residues linked glycosidically in branched or unbranched chains.

“Progenitor cell” as used herein refers to a cell that gives rise to progeny in a defined cell lineage.

“Promote” and/or “promoting” as used herein refer to an augmentation in a
15 particular behavior of a cell or organism. In one embodiment, promoting relates to the mobilization of melanocyte derived stem cells. In another embodiment, promoting relates to the differentiation of stem cells into melanocytes.

“Recruitment” of a stem cell as used herein refers to a process whereby a
20 stem cell in the circulatory system migrates into specific site within a tissue or organ. Recruitment may be facilitated by a compound or molecule, such as a chemoattractant signal or cell receptor. For example, both CXCR4 and SDF-1 have identified roles in stem cell homing and migration.

“Releasing agent” as used herein are mobilization agents capable of
25 promoting the release and egress of stem cells from a tissue of origin. Release of stem cells from a tissue of origin may be demonstrated, for example, by an increase in circulating stem cells in the circulatory or immune system, or by the expression of markers related to egress of stem cells from a tissue of origin, such as bone marrow. Examples of releasing agents include fucoidan, as obtained from an extract of algae
30 such as *Undaria pinnatifida*. In one embodiment, the releasing agent increases the number of bone marrow-derived stem cells and/or hematopoietic stem cells in the peripheral blood. In another embodiment, the releasing agent affects the number of stem cells, such as CD34^{high} (CD34+) cells, circulating in the peripheral blood.

“Satellite cell” as used herein refers to a muscle-specific stem cell, often located in the periphery of muscle tissue, and capable of migrating into a muscle to aid in tissue repair and reconstruction.

“Stem cells” as used herein are cells that are not terminally differentiated and are therefore able to produce cells of other types. Characteristic of stem cells is the potential to develop into mature cells that have particular shapes and specialized functions, such as heart cells, skin cells, or nerve cells. Stem cells are divided into three types, including totipotent, pluripotent, and multipotent. “Totipotent stem cells” can grow and differentiate into any cell in the body and thus, can form the cells and tissues of an entire organism. “Pluripotent stem cells” are capable of self-renewal and differentiation into more than one cell or tissue type. “Multipotent stem cells” are clonal cells that are capable of self-renewal, as well as differentiation into adult cell or tissue types. Multipotent stem cell differentiation may involve an intermediate stage of differentiation into progenitor cells or blast cells of reduced differentiation potential, but are still capable of maturing into different cells of a specific lineage. The term “stem cells”, as used herein, refers to pluripotent stem cells and multipotent stem cells capable of self-renewal and differentiation. “Bone marrow-derived stem cells” are the most primitive stem cells found in the bone marrow which can reconstitute the hematopoietic system, possess endothelial, mesenchymal, and pluripotent capabilities. Stem cells may reside in the bone marrow, either as an adherent stromal cell type, or as a more differentiated cell that expresses CD34, either on the cell surface or in a manner where the cell is negative for cell surface CD34. “Adult stem cells” are a population of stem cells found in adult organisms with some potential for self-renewal and are capable of differentiation into multiple cell types. Other examples of stem cells are marrow stromal cells (MSCs), HSC, multipotent adult progenitor cells (MAPCs), very small embryonic-like stem cells (VSEL), epiblast-like stem cell (ELSC) or blastomere-like stem cell (BLSC).

“Stem cell circulation agent” (SCCA), “mobilization agent”, and/or “mobilization factor” as used herein refers to one or more compounds, antibodies, nucleic acid molecules, proteins, polysaccharides, cells, or other molecules, including, but not limited to, neuropeptides and other signaling molecules, that affects the release, circulation, homing and/or migration of stem cells from the circulatory system into tissue or organ. A molecular agent may be a naturally occurring molecule or a synthetic molecule. Examples of mobilization agents include

“releasing agents”, wherein a releasing agent is capable of promoting the egress of stem cells from a tissue of origin and also “migration agents”, wherein a migration agent is capable of promoting the process of a cell moving from the circulatory system into a tissue or organ.

5 “Subject” as used herein includes all animals, including mammals and other animals, including, but not limited to, companion animals, farm animals and zoo animals. The term “animal” can include any living multi-cellular vertebrate organisms, a category that includes, for example, a mammal, a bird, a simian, a dog, a cat, a horse, a cow, a rodent, and the like. Likewise, the term “mammal” includes
10 both human and non-human mammals.

 “Therapeutically effective amount” as used herein refers to the quantity of a specified composition, or active agent in the composition, sufficient to achieve a desired effect in a subject being treated. For example, this can be the amount effective for enhancing migration of stem cells that replenish, repair, or rejuvenate
15 tissue. In another embodiment, a “therapeutically effective amount” is an amount effective for enhancing trafficking of stem cells, such as increasing release of stem cells, as can be demonstrated by elevated levels of circulating stem cells in the bloodstream. In still another embodiment, the “therapeutically effective amount” is an amount effective for enhancing homing and migration of stem cells from the
20 circulatory system to various tissues or organs, as can be demonstrated by decreased level of circulating stem cells in the bloodstream and/or expression of surface markers related to homing and migration. A therapeutically effective amount may vary depending upon a variety of factors, including but not limited to the physiological condition of the subject (including age, sex, disease type and stage,
25 general physical condition, responsiveness to a given dosage, desired clinical effect) and the route of administration. One skilled in the clinical and pharmacological arts will be able to determine a therapeutically effective amount through routine experimentation.

 “Trafficking” as used herein refers to the process of movement of a cell from
30 the tissue of origin, traveling within the circulatory or immune system, and localization towards a site within a tissue and/or organ. Trafficking also includes stem cell mobilization, beginning with release from a tissue of origin, such as egress of stem cells from bone marrow. Trafficking further includes movement of a cell from the tissue of origin, homing by adhesion to the endothelium, transmigration, and final

migration within the target tissue and/or organ. Furthermore, trafficking may include the process of movement of a cell of the immune system. One specific, non-limiting example of trafficking is the movement of a stem cell to a target organ, also referred to as migration. Another specific, non-limiting example of trafficking is the movement
5 of a B-cell or a pre-B-cell leaving the bone marrow and moving to a target organ.

“Treat,” “treating” and “treatment” as used herein refer to both therapeutic treatment and prophylactic or preventative measures, wherein the object is to prevent or slow down (lessen) the targeted condition, disease or disorder (collectively “ailment”) even if the treatment is ultimately unsuccessful. Those in
10 need of treatment may include those already with the ailment as well as those prone to have the ailment or those in whom the ailment is to be prevented.

As described, stem cells are unique cells which possess the capacity to differentiate into more specialized cells. One particular type of stem cell,
15 hematopoietic stem cells (HSCs), are capable of differentiating into many different types of blood cells. In addition, HSCs typically reside in the bone marrow, where proliferation and self-renewal of the cells allows HSCs to be involved in the support and maintenance of the hematopoietic system. Existing scientific literature has chiefly focused on HSCs’ potential to develop into hematopoietic lineage cells
20 derivatives. Emerging evidence has further identified the capacity for HSCs to also differentiate into non-hematopoietic, tissue specific cells. Recently, HSCs have been found to possess the capacity to differentiate into a variety of tissue-specific cell types, such as myocytes, hepatocytes, osteocytes, glial cells, and neurons. As a result, HSCs form blood and immune cells that are responsible for constant
25 maintenance and immune protection of virtually every cell type of the body.

Similarly, bone marrow stem cells (BMSCs) were recently shown to have significant capability to become cells of other tissues. In the bone marrow, stem cells duplicate using a process known as “asymmetrical cellular division” according to which the two daughter cells are not identical; one cell retains the original DNA
30 and remains in the bone marrow whereas the other cell contains the DNA copies and is released in the blood where it migrates into various tissues in need of repair. BMSCs have been traditionally considered to have little potential for plasticity, being limited in their development to red blood cells, lymphocytes, platelets, bone and connective tissue. However, much scientific work has been published over the past

few years that demonstrates the exceptional plasticity of BMSC. For example, after transplantation, BMSCs and HSCs were shown to have the ability to become muscle cells (Abedi et al., 2004), heart cells (Fraser et al., 2004), endothelium capillary cells (Asahara et al., 1999), liver cells (Jang et al., 2004), as well as lung, (Krause et al., 5 2001), gut (Krause et al., 2001), skin (Branski et al., 2008), and brain cells (Dezawa et al., 2005). As a further illustrative example, Jang et al. (2004) performed an experiment which not only demonstrated the ability of HSC to become liver cells upon contact with specific liver-derived molecules, but this process took place within hours. Briefly, HSCs were co-cultured with either normal or damaged liver tissue 10 separated by a semi-permeable membrane (pores large enough to let molecules pass through, but small enough to prevent the passage of cells from one compartment to the other, pore size 0.4 μm). Using immunofluorescence assay methods to detect molecules specific for either HSCs (CD45) or liver cells (albumin), the researchers could follow the transformation of the population of cells placed in 15 the upper compartment. When HSCs were cultured alone for 8 hours, they only expressed CD45 and no albumin, indicating that no HSCs had differentiated into liver cells. However, when HSCs were exposed to injured liver tissue, they rapidly became positive for albumin. Over time, the population of cells positive for CD45 began to decrease as the population positive for albumin began to increase. 20 Albumin-positive cells were seen as early as 8 hours into the procedure and increased in frequency to 3.0% at 48 hours. The conversion was minimal and delayed when HSCs were exposed to undamaged liver (control for injury).

Because HSCs and BMSCs play an important role in the healing and regenerative processes of various tissues and organs in the body beyond their 25 traditional role in maintaining hematopoietic and immune systems of the body, activation and enhancement of stem cell trafficking may amplify these physiological processes and provide a potential therapy for various pathologies. The classic source of HSCs and BMSCs is bone marrow, which includes hip, ribs, sternum and other bone structures. Bone provides a unique regulatory microenvironment for 30 HSCs and BMSCs, including interaction with a specific mesenchymal cell type (the osteoblast), extracellular matrix glycoproteins and a uniquely rich mineral signature. (Adams and Scadden, 2006) This stem cell “niche” contains a great deal of critical molecular interactions which guide the response of stem cells to specific physiological conditions. The niche may be an important focal point for changes in

the state of tissue that result in a change in the regenerative processes rooted in stem cell activity. (Adams and Scadden, 2006)

Beyond populations of HSCs found in bone marrow, HSCs are also present in the peripheral bloodstream of normal, healthy persons. It has been known for decades that a small number of stem and progenitor cells circulate in the bloodstream, but more recent studies have shown that greater numbers of HSCs can be coaxed into mobilization from marrow to blood by injecting the donor with a cytokine, such as granulocyte-colony stimulating factor (G-CSF). Despite this advance, the natural process by which stem cells are released from bone marrow and migrate towards a site within tissue and/or an organ is not fully understood. A leading model involves the chemokine, Stromal-Derived Factor-1 (SDF-1) and its specific receptor, CXCR4. In this capacity, the binding of SDF-1 to CXCR4, leads to adherence of stem cells to bone marrow through increased expression of adhesion molecules on the cell membrane surface. Disruption of adhesion of stem cells to bone marrow thus promotes mobilization of stem cells into the peripheral bloodstream. (Figure 1C) Some factors such as G-CSF or IL-8 may interfere with adhesion through elevated activation of proteolytic enzymes or degradation of the SDF-1 ligand. (Drapeau 2010) Other types of molecules, such as L-selectin blockers, may instead down-regulate CXCR4 expression which in turn reduces stem cell adhesion to the bone marrow environment. Generally speaking enhancing binding of SDF-1 to CXCR4 promote adherence, therefore L-selectin blockers such as sulfated fucans, which reduces CXCR4 expression, can trigger stem cell mobilization. (Drapeau 2010)

Stem cells circulating in the peripheral bloodstream are recruited to sites of tissue in need of repair and regeneration through homing and extravasation. This mobilization of stem cells into the bloodstream and subsequent migration to the site of tissue injury results from a combination of mechanical and chemoattractant signals. (Drapeau 2010) Mechanical force or other factors may activate L-selectins on the surface of stem cells. Activation of L-selectins, in turn, may promote elevated expression of the receptor, CXCR4. Cells at the site of tissue injury may also secrete SDF-1 ligand, thereby attracting stem cells expressing receptor CXCR4 to the injury site. The interaction of SDF-1 and CXCR4 promotes sufficient adhesion to halt circulation of a stem cell in the peripheral blood stream. (Figure 1B) Based on this model, L-selectin blockers such as sulfated fucans, may possess a critical

capacity to mobilize HSCs into the bloodstream, with subsequent homing, extravasation and migration into tissue promoting regenerative maintenance and repair of cells and tissues in an organism. Whereas G-CSF is released from injured tissue and its presence in the bloodstream triggers HSC release from bone marrow, dietary supplements composed of L-selectin blockers may possibly support the phenomenon of natural regeneration and repair in the body.

Fucoidan. Fucoidan is a sulfated fucan polysaccharide L-selectin agonist that was documented to promote the egress of HSCs from compartments in bone marrow into the peripheral blood stream upon intravenous injection, although this effect seemed unrelated to its stimulation of L-selectin (Frenette et al., 2000). Circulation of HSCs in the peripheral bloodstream is a critical step in promoting the stem cell regeneration and repair mechanisms in the body. As a sulfated fucan, fucoidan is found in various species of algae. Other sulfated fucans have also been found in animal species, such as echinoderms (e.g., sea urchins and sea cucumbers).

Despite *in vivo* data in animal models that demonstrate significantly elevated levels of HSCs following intravenous fucoidan administration, observations of positive clinical effects in human subjects are much more limited. Reported studies have shown that the percentage of HSCs expressing an important trafficking receptor, CXCR4, increased significantly following 4 days of oral fucoidan administration. (Irhimeh et al., 2007) However, only a slight change was observed in the absolute number of HSCs circulating in peripheral blood.

As described, fucoidan (also known as fucoidin or fucansulfate in the art) is a sulfated fucose polysaccharide L-selectin ligand. Selectin activity depends on important carbohydrate or polypeptide modifications such as sialylation, fucosylation, and sulfation. The presence of binding sites for sulfated fucans such as fucoidan on P- and L-Selectin has been demonstrated to be at least partially the mechanism by which fucoidan promotes detachment of HSCs from BM. (Frenette et al., 2000, 2461, Jensen et al., 2007, 190) Perhaps more significantly, sulfated fucans such as fucoidan, have been shown to displace SDF-1 sequestered on endothelial surfaces or bone marrow through competitive binding to a heparin-binding domain present on SDF-1. Occupation of the heparin-binding site of SDF-1 by fucoidan prevents tethering to cell surfaces, thereby increasing circulating SDF-1 levels in plasma. (Sweeney et al., 2008) Without being bound by any particular theory, the enhanced

5 levels of SDF-1 ligand in the bloodstream may thus promote egress of CXCR4 receptor expressing HSCs from the BM. (Sweeney et al., 2008) (Figure 1C) Based on this model, the inventors hypothesized that L-selectin ligand, such as fucoidan, may possess a critical capacity to mobilize HSCs and oral administration of dietary supplements composed of fucoidan may best support natural regeneration and repair in the body.

10 Compelling *in vivo* data in animal models demonstrates significantly elevated levels of circulating HSCs following intravenous (IV) fucoidan administration in mice and primates, although significant drawbacks would present limitations for human therapeutic use. Recent reports have shown a dramatic 12-fold increase in levels of circulating HSCs, HSC progenitors and derivative cell types (including erythroid burst forming units, granulocyte, erythroid, macrophage, megakaryocyte colony forming units, granulocyte, erythroid, macrophage, and granulocyte macrophage colony-forming units) compared to untreated controls, 3 hours following injection of fucoidan (source unknown) into mice. Similar results of sustained elevation in levels of HSCs, HSCs progenitors and derivative cell types, were reported after daily injections for 3 days. (Sweeney et al., 2008) Injection of fucoidan in primates has also been demonstrated to increase HSCs and HSC-derivative levels by 11-26 fold after 6 hours after administration, with sustained elevation still observable up to 24 hours later. (Sweeney et al., 2000) Despite these positive observations, several challenges could impede therapeutic use of fucoidan in human subjects. The temporary and transitory effect of elevated HSCs circulating and bone marrow-derived stem cells may fail to fully realize the positive clinical benefits of stem cell regenerative and repair mechanisms, since sustained or repeated periods of elevation may be needed to enable stem cell homing and extravasation processes that underlie therapeutic stem cell activity. This limitation is further compounded in view of the difficulty and inconvenience of routinely administering IV injections.

25 Existing observations in human subjects are limited and available data on oral fucoidan administration in humans does not mirror the positive clinical effects of animal studies using IV injection. Reported studies by others have shown that the percentage of HSCs expressing an important trafficking receptor, CXCR4, increased significantly (45% to 90%) after 12 days of oral fucoidan administration (3 grams daily of 10% w/w or 75% w/w fucoidan extracts from *Undaria pinnatifida*). However, only a slight change (~ 12%) was observed in the absolute number of HSCs

circulating in peripheral blood (maximal effect was 1.64 to 1.85 cells/ μ l after 4 days of fucoidan extract administration). (Irhimeh et al., 2007) Importantly, for therapeutic applications involving oral administration, fucoidan is capable of surviving acidic conditions in the stomach and does not demonstrate adverse side effects. (Irhimeh et al., 2007) This is consistent with reports that catalytic fucoidinase, which metabolizes fucoidan, is found only in marine invertebrates and not terrestrial mammals. (Berteau and Mulloy, 2003) This may provide an vital therapeutic benefit of high persistence and stability of an administered sulfated fucan, including fucoidan, for sustained therapeutic effect. It is particularly ideal for oral uses where diffusion into the bloodstream must first survive enzymatic processing in the mouth, esophagus, and intestines, in addition to the highly acidic conditions of the stomach.

The inventors have discovered that the source of fucoidan and appropriate dosing regimens are critical features for promoting HSC mobilization through oral fucoidan administration. Fucoidan is a member of the broader class of sulfated fucans, which are polysaccharides rich in L-fucose and obtained primarily from two sources: algae and marine invertebrates. Sulfated fucans obtained from these two sources differ greatly in composition and structure. This diversity of molecular structure further exists across fucoidans from different species of algae. While generally described as ~20,000 molecular weight polysaccharide composed of L-fucose, exact fucoidan structures depend in-part, on the source organism. As example, the most well-studied fucoidan from *F. vesiculosus*, is reported to be composed primarily of L-fucose with $\alpha(1\rightarrow3)$ glycosidic bonds and sulfate groups at position 4, with sulfated fucose branches every 5 units. In contrast, fucoidan from a different algae, *Ascophylum nodosum*, has a large proportion of repeating $\alpha(1\rightarrow3)$ and $\alpha(1\rightarrow4)$ glycosidic bonds that alternate for oligosaccharide formation, possibly with few sulfated branching points as showing in nuclear magnetic resonance (NMR) studies (Berteau, 2003). In sum, fucoidans from different species are structurally distinct, heterogeneous and diverse.

The present invention provides new compositions and methods for providing a wide range of clinical and physiological benefits to a subject in need thereof by the administration of a mobilization agent. While not wishing to be bound by any particular theory, the inventors believe that the beneficial and other physiological results obtained through administration of the inventive compositions result from

enhancing stem cell trafficking and migration that follows the administration of the mobilization agent.

In various embodiments, the mobilization agent comprises one or more components selected from the group including: *Lycium Barabrum*, colostrum, mushroom polysaccharides (e.g., *Cordyceps sinensis*, *Hericium erinaceus* (Lion's mane), *Ganoderma lucidum* (Reishi)), fucoidan (optionally extracted from algae, e.g., *Undaria pinnatifida*, *Chordaria cladosiphon* (Limu)), spirulina (e.g., *Arthrospira platensis*, *Arthrospira maxima*), analogs thereof, derivatives thereof, extracts thereof, synthetic or pharmaceutical equivalents thereof, fractions thereof, and combinations of any of the foregoing items. The mobilization agents may be combined together in one or more compositions or they may be administered or consumed separately as part of a regimen. They may have individual physiological effects, additive effects and/or synergistic effects with one another, such as serving as both a releasing agent and migration agent. In some embodiments, the mobilization agent is capable of functioning as a migration agent, promoting the process of a cell moving from the circulatory system into a tissue or organ. In some embodiments, the mobilization agent is capable of functioning as a releasing agent, promoting the release and egress of stem cells from a tissue of origin.

In one embodiment, a mobilization agent is administered to a subject, for example *Lycium Barbarum*, though the subject may be provided a mixture of *Lycium Barbarum* and other mobilization agents. In some embodiments, the subject consumes and digests whole *Lycium Barbarum berries*. The berries may be fresh, frozen, freeze-dried, dehydrated, or preserved in some other manner. Therefore, *Lycium Barbarum*, as described herein, encompasses both whole berry and extracts thereof. In one embodiment, the mobilization agent is an extract of *Lycium Barbarum*, or an isolated component or compound extracted from *Lycium Barbarum*, such as a compound found in a polysaccharide-rich fraction of *Lycium Barbarum* extract. *Lycium Barbarum* can be provided alone as an isolated or purified substance, or may be part of a composition including a pharmaceutically acceptable carrier. In one embodiment, *Lycium Barbarum* is capable of functioning as a migration agent.

In one embodiment, colostrum is administered to a subject, though the subject may be provided a mixture of colostrum and other mobilization agents. In some embodiments, the subject consumes and digests whole colostrum. The colostrum

may be fresh, frozen, freeze-dried, dehydrated, or preserved in some other manner. Therefore, colostrum, as described herein, encompasses both whole colostrum and extracts thereof. In one embodiment, the mobilization agent is an extract of colostrum, or an isolated component or compound extracted from colostrum, such as
5 a compound found in a protein-rich fraction of colostrum extract colostrum can be provided alone as an isolated or purified substance, or may be part of a composition including a pharmaceutically acceptable carrier. In one embodiment, colostrum is capable of functioning as a migration agent.

In one embodiment, mushroom or a blend of mushrooms is administered to a
10 subject, though the subject may be provided a mixture of mushrooms and other mobilization agents. In some embodiments, the subject consumes and digests whole mushrooms. The mushrooms may be fresh, frozen, freeze-dried, dehydrated, or preserved in some other manner. Therefore, mushrooms, as described herein, encompass both whole mushrooms and extracts thereof. In one embodiment, the
15 agent is *Cordyceps sinensis* or an extract thereof. In one embodiment, the mobilization agent is *Ganoderma lucidum* or an extract thereof. In one embodiment, the mobilization agent is *Hericium erinaceus* or an extract thereof. Mushrooms can be provided alone as isolated or purified substances, or may be part of a composition including a pharmaceutically acceptable carrier. In one embodiment,
20 mushrooms, *Cordyceps sinensis*, *Ganoderma lucidum*, and/or *Hericium erinaceus* is capable of functioning as a migration agent.

In one embodiment, algae is administered to a subject, though the subject may be provided a mixture of algae and other mobilization agents. In some
25 embodiments, the subject consumes and digests whole algae. The algae may be fresh, frozen, freeze-dried, dehydrated, or preserved in some other manner. Therefore, algae, as described herein, encompass both whole mushrooms and extracts thereof. In one embodiment, the mobilization agent is *Chordaria cladosiphon* or an extract thereof. Algae can be provided alone as isolated or purified substances, or may be part of a composition including a pharmaceutically
30 acceptable carrier. In one embodiment, algae, *Chordaria cladosiphon* is capable of functioning as a migration agent.

In one embodiment, spirulina is administered to a subject, though the subject may be provided a mixture of spirulina and other mobilization agents. In some
embodiments, the subject consumes and digests whole spirulina. The spirulina may

be fresh, frozen, freeze-dried, dehydrated, or preserved in some other manner. Therefore, spirulina, as described herein, encompasses both whole spirulina and extracts thereof. In one embodiment, the mobilization agent is *Arthrospira platensis*, *Arthrospira maxima*, or an extract thereof. Spirulina can be provided alone as an isolated or purified substance, or may be part of a composition including a pharmaceutically acceptable carrier. In one embodiment, spirulina is capable of functioning as a migration agent.

A method is described herein for enhancing stem trafficking by administering to a subject a therapeutically effective amount of fucoidan.

In one embodiment, an algae, such as *Undaria pinnatifida*, is administered to a subject, though the subject may be provided a mixture of more than one algae. In some embodiments, the subject consumes and digests whole plant or parts of the plant. The algae may be fresh, frozen, freeze-dried, dehydrated, or preserved in some other manner.

In alternative embodiments, an extract of the algae is provided or administered to the subject. In another embodiment, the algae encompasses both whole plant and extracts thereof. In another embodiment, the algae can be provided alone as an isolated or purified substance, or may be part of a composition including a pharmaceutically acceptable carrier. In another embodiment, the extract is a highly sulfated, polyanionic soluble fiber. In one embodiment, the extract is an isolated fucoidan. In a different embodiment, the fucoidan is purified following isolation. In an alternative embodiment, a polysaccharide fraction is administered to the subject. In another embodiment, the highly sulfated, polyanionic soluble fiber is administered to the subject. In one, the isolated fucoidan is administered to the subject. In a different embodiment, the purified fucoidan is administered to the subject. In one embodiment, *Undaria pinnatifida* is capable of functioning as a releasing agent after administration to a subject.

The present invention further provides a pharmaceutical preparation. In one embodiment, the pharmaceutical preparation is 90% w/w fucoidan. In another embodiment, the pharmaceutical preparation is 80% w/w fucoidan. In one embodiment, the pharmaceutical preparation is 75% w/w fucoidan. In another embodiment, the pharmaceutical preparation is 70% w/w fucoidan. In another

embodiment, the pharmaceutical preparation is 60% w/w fucoidan. In another embodiment, the pharmaceutical preparation is 50% w/w fucoidan. In another embodiment, the pharmaceutical preparation is 40% w/w fucoidan. In another embodiment, the pharmaceutical preparation is 30% w/w fucoidan. In another
5 embodiment, the pharmaceutical preparation is 20% w/w fucoidan. In another embodiment, the pharmaceutical preparation is 10% w/w fucoidan.

The present invention further provides a dosing regimen. In one embodiment, the dosing regimen is dependent on the severity and responsiveness of a disease
10 state to be treated, with the course of treatment lasting from a single administration to repeated administration over several days and/or weeks. In another embodiment, the dosing schedule is based on measurement of an active component accumulated in the body. In a certain embodiment, the active component is fucoidan. In one
15 embodiment, the fucoidan is isolated from *Undaria pinnatifida* or extracts thereof. In another embodiment, the dosing regimen is dependent on the level of stem cell trafficking in the subject. In one embodiment, the dosing regimen is dependent on the activity of a releasing agent administered to a subject. In another embodiment, the dosing regimen is dependent on the number of circulating CD34+ HSCs in the
20 peripheral blood stream of a subject. In another embodiment, the dosing regimen is dependent on the number of circulating bone marrow-derived stem cells in the peripheral blood stream of a subject. In one embodiment, the dosing regimen is 3 grams of fucoidan administered daily. In another embodiment, the dosing regimen is 1 gram of fucoidan administered daily. In another embodiment, the dosing
25 regimen is 500 mg grams of fucoidan administered daily. In another embodiment, the dosing regimen is 75 mg grams of fucoidan administered daily. In one embodiment, the dosing regiment is 250 mg grams of fucoidan administered daily.

The present invention further provides a method of enhancing the trafficking of stem cells in a subject. In one embodiment, the level of trafficking of stem cells
30 relates to the number of circulating CD34+ HSCs in the peripheral blood of a subject. In another embodiment, the level of trafficking of stem cells relates to the number of circulating bone marrow-derived stem cells in the peripheral blood of a subject. In another embodiment, the method provided herein enhances the trafficking of stem cells in a subject, comprising administering a therapeutically effective amount of a

polysaccharide fraction of an algae extract, thereby enhancing the trafficking of stem cells in the subject. In another embodiment, the method provided herein enhances the trafficking of stem cells in a subject, comprising administering a highly sulfated, polyanionic soluble fiber of an algae extract, thereby enhancing the trafficking of stem cells in the subject. In another embodiment, the method provided herein enhances the trafficking of stem cells in a subject, comprising administering a highly sulfated, polyanionic soluble fiber of an algae extract, thereby enhancing the trafficking of stem cells in the subject. In a certain embodiment, the method provided herein enhances the trafficking of stem cells in a subject, comprising administering isolated fucoidan from an algae extract, thereby enhancing the trafficking of stem cells in the subject. In a different embodiment, the method provided herein enhances the trafficking of stem cells in a subject, comprising administering purified fucoidan from an algae extract, thereby enhancing the trafficking of stem cells in the subject.

In another embodiment, the method provided herein enhances the trafficking of stem cells in a subject, including administering a therapeutically effective amount of a composition containing one or more of the following components selected from the group including: *Lycium barbarum* or extracts thereof, colostrum or extracts thereof, spirulina or extracts thereof, *Arthrospira platensis* or extracts thereof, *Arthrospira maxima* or extracts thereof, fucoidan or extracts thereof, *Chordaria cladosiphon* or extracts thereof, *Hericium erinaceus* or extracts thereof, *Ganoderma Lucidum* or extracts thereof, and/or *Cordyceps Sinensis* or extracts thereof, thereby enhancing the trafficking of stem cells in the subject. In one embodiment, enhancement of stem cell trafficking may be measured by assaying the response of stem cells to a particular dose of a composition containing one or more of the following components selected from the group including: *Lycium barbarum* or extracts thereof, colostrum or extracts thereof, spirulina or extracts thereof, *Arthrospira platensis* or extracts thereof, *Arthrospira maxima* or extracts thereof, fucoidan or extracts thereof, *Chordaria cladosiphon* or extracts thereof, *Hericium erinaceus* or extracts thereof, *Ganoderma Lucidum* or extracts thereof, and/or *Cordyceps Sinensis* or extracts thereof, thereby enhancing the trafficking of stem cells in the subject.

In another embodiment, the method provided herein enhances the trafficking of stem cells in a subject, including administering a therapeutically effective amount

of a composition containing fucoidan. In one embodiment, enhancement of stem cell trafficking may be measured by assaying the response of stem cells to a particular dose of a composition containing fucoidan. In one embodiment, the fucoidan is from *Undaria pinnatifida* or extracts thereof.

5

The present invention further provides a method for enhancing the trafficking of stem cells in a subject, comprising administering a therapeutically effective amount of a mobilization agent or a polysaccharide fraction of a mobilization agent, thereby increasing the release, circulation, homing and/or migration of stem cells in
10 the subject, regardless of the route of administration.

The present invention further provides of a method of inducing a transient decrease in the population of circulating stem cells, such as CD34+ stem cells. Enhancement of stem cell migration may be measured by assaying the response of stem cells to a particular dose of *Lycium Barbarum*. In one embodiment, providing a
15 mobilization agent to a subject will enhance migration of that subject's stem cells within a certain time period, such as less than about 5 hours, less than about 4 hours, less than about 2 hours, or less than about 1 hour following administration. In other embodiments, the mobilization agent is colostrum, mushroom polysaccharides including *Cordyceps sinensis*, *Hericium erinaceus*, *Ganoderma lucidum*, fucoidan
20 including *Chordaria cladosiphon*, spirulina, including *Arthrospira platensis*, and/or *Arthrospira maxima*.

In another embodiment, administration of an extract of algae increases the rate of homing of stem cells measured by a transient decrease in the number of circulating stem cells within the subject's body. In another embodiment, the algae is
25 *Chordaria cladosiphon*. In another embodiment, the percentage decrease in the number of circulating stem cells compared to a normal baseline may about 25%, about 50%, about 75%, or even about 100% as compared to a control. In one embodiment, the control is a base line value from the same subject. In another embodiment, the control is the number of circulating stem cells in an untreated
30 subject, or in a subject treated with a placebo or a pharmacological carrier.

In one embodiment, administration of a mobilization agent results in the migration of stem cells from the circulation to tissues from about 1 to about 3 hours following administration. Circulating stem cells will leave the circulatory system, thus decreasing the number of circulating stem cells within the subject's body. The

percentage decrease in the number of circulating stem cells compared to a normal baseline may be about 15%, about 30%, about 50% or greater than about 75% decrease as compared to a control. In one embodiment, the control is a base line value from the same subject. In another embodiment, the control is the number of circulating stem cells in an untreated subject, or in a subject treated with a placebo or a pharmacological carrier.

In another embodiment, administration of an extract of a mobilization agent increases the rate of homing of stem cells measured by a transient decrease in the number of circulating stem cells within the subject's body. The percentage decrease in the number of circulating stem cells compared to a normal baseline may be about 25%, about 50%, about 75%, or even about 100% as compared to a control. In one embodiment, the control is a base line value from the same subject. In another embodiment, the control is the number of circulating stem cells in an untreated subject, or in a subject treated with a placebo or a pharmacological carrier. In another embodiment, the administration of an extract of a mobilization agent leads to an increase in CXCR4 expression on circulating stem cells.

The present invention further provides a method of inducing a transient increase in the population of circulating stem cells, such as CD34+ stem cells following administration of an algae extract. In one embodiment, the stem cells are hematopoietic stem cells (HSCs). In another embodiment, the stem cells are bone marrow-derived stem cells. In one embodiment, enhancement of stem cell trafficking may be measured by assaying the response of stem cells to a particular dose of algae extract. In one embodiment, providing algae extract to a subject will enhance release of that subject's stem cells within a certain time period, such as less than 12 days, less than 6 days, less than 3 days, less than 2, or less than 1 days. In an alternative embodiment, the time period is less than 12 hours, 6 hours, less than about 4 hours, less than about 2 hours, or less than about 1 hour following administration. In another embodiment, the stem cells are bone marrow-derived stem cells. In one embodiment, the algae extract is from *Undaria pinnatifida*.

In one embodiment, administration of algae extract results in the release of stem cells into the circulation from about 2 to about 3 hours following administration. In another embodiment, released stem cells enter the circulatory system and increase the number of circulating stem cells within the subject's body. In another

embodiment, the percentage increase in the number of circulating stem cells compared to a normal baseline may about 25%, about 50%, about 100% or greater than about 100% increase as compared to a control. In one embodiment, the control is a base line value from the same subject. In another embodiment, the control is the number of circulating stem cells in an untreated subject, or in a subject treated with a placebo or a pharmacological carrier.

In some embodiments, the subject administered a mobilization agent is healthy. In other embodiments, the subject is suffering from a disease or physiological condition, such as immunosuppression, chronic illness, traumatic injury, degenerative disease, infection, or combinations thereof. In certain embodiments, the subject may suffer from a disease or condition of the skin, digestive system, nervous system, lymph system, cardiovascular system, endocrine system, or combinations thereof. In specific embodiments, the subject suffers from osteoporosis, Alzheimer's disease, cardiac infarction, Parkinson's disease, traumatic brain injury, multiple sclerosis, cirrhosis of the liver, any of the diseases and conditions described in the Examples below, or combinations thereof. Administration of a therapeutically effective amount of a mobilization agent may prevent, treat and/or lessen the severity of or otherwise provide a beneficial clinical benefit with respect to any of the aforementioned conditions, although the application of the inventive methods and use of the inventive mobilization agent is not limited to these uses. In various embodiments, the novel compositions and methods find therapeutic utility in the treatment of, among other things, skeletal tissues such as bone, cartilage, tendon and ligament, as well as degenerative diseases, such as Parkinson's and diabetes. Enhancing the release, circulation, homing and/or migration of stem cells from the blood to the tissues may lead to more efficient delivery of stem cells to a defect site for increased repair efficiency. The novel compositions and methods of the present invention may also be used in connection with gene therapeutic approaches.

30

The present invention further provides various compositions for administration to a subject. In one embodiment, the administration is topical, including ophthalmic, vaginal, rectal, intranasal, epidermal, and transdermal. In one embodiment, the administration is oral. In one embodiment, the composition for oral administration

includes powders, granules, suspensions or solutions in water or non-aqueous media, capsule, sachets, tablets, lozenges, or effervescent. In another embodiment, the composition for oral administration further comprises thickeners, flavoring agents, diluents, emulsifiers, dispersing aids or binding agents.

5

Described herein are mobilization agents and methods of using mobilization agents towards promoting stem cell trafficking. Further described herein are migration agents and method of using migration agents to promote the process of stem cells moving from the circulatory system into a tissue or organ. Also described
10 herein are releasing agents and methods of using releasing agents to promote egress of stem cells from a tissue of origin. Also described herein is a method of oral administration of fucoidan which results in a significant release of HSCs into peripheral blood circulation. The inventors have demonstrated effective administration of stem cell mobilization agents, thereby achieving a safe, convenient
15 and effective method to enhance stem cell-related maintenance and repair in the human body. Although the pathology of stem cells is of great importance and interest, and pertains to the subject matter disclosed herein, the underlying scope of this invention is that the release, circulation, homing and/or migration of stem cells from the blood to tissues is of significance in repairing injured tissue and maintaining
20 the vitality and health of existing tissue. Thus, the importance of developing methods and compositions for achieving this end are among the foci and aims of the present invention.

Accordingly, the present invention provides novel compositions and methods for, among other things, enhancing natural tissue healing and renewal in the body by
25 supporting the trafficking of stem cells. Furthermore, the present invention provides novel compositions and methods for preventing, slowing or otherwise diminishing the development of health problems in a mammal by promoting trafficking of stem cells in the mammal. The compositions and methods disclosed herein may further increase regeneration of existing tissue by supporting the release, circulation,
30 homing and/or migration of stem cells into tissue, therefore supporting the process of tissue repair.

EXAMPLES

The following examples are provided to better illustrate the claimed invention and are not to be interpreted as limiting the scope of the subject matter. To the extent that specific materials are mentioned, it is merely for purposes of illustration and is not intended to limit the invention. One skilled in the art may develop equivalent means, compositions or reactants without the exercise of inventive capacity and without departing from the scope of the present invention.

Example 1

Production and Preparation of L. Barbarum

Polysaccharides from *Lycium Barbarum* were prepared by the method of Luo et al. (2004). The dried fruit samples (100 g) were ground to fine powder and put in 1.5 l of boiling water and decocted for 2 h by a traditional method for Chinese medicinal herbs. The decoction was left to cool at room temperature, filtered and then freeze-dried to obtain crude polysaccharides.

The dried crude polysaccharides were refluxed three times to remove lipids with 150 ml of chloroform:methanol solvent (2:1) (v/v). After filtering the residues were air-dried. The result product was extracted three times in 300 ml of hot water (90 °C) and then filtered. The combined filtrate was precipitated using 150 ml of 95% ethanol, 100% ethanol and acetone, respectively. After filtering and centrifuging, the precipitate was collected and vacuum-dried, giving desired polysaccharides (13 g). The content of the polysaccharides was measured by phenolsulfuric method (Masuko et al., 2005). Result showed that the content of the polysaccharides in the extract may reach 97.54%.

Example 2

Stem Cells Migrate following Lycium Barbarum Consumption

Consumption of *Lycium Barbarum*, or compounds thereof, enhances recruitment and migration of CD34+ stem cells (see FIG. 2 for a diagram of stem cells entering the circulatory system).

Healthy human volunteers were identified, and the proportion of CD34+ cells was evaluated in the peripheral blood (circulating CD34+ cells) of each person prior to consumption of *Lycium Barbarum* and hourly for up to 4 hours after consumption.

The volunteers were instructed to limit physical and mental activity for a time before and after consumption of *Lycium Barbarum*.

Each person was provided 5 grams of dried *Lycium Barbarum* or 1 gram of polysaccharide extracted from *Lycium Barbarum*. Red blood cells in whole blood samples obtained from each volunteer were lysed using FACS lysing solution (Beckton Dickenson, San Jose, Calif.). The remaining cells were washed and stained with monoclonal antibody HPCA-2 conjugated with fluorescein isothiocyanate. Samples were fixed in 1% formalin and analyzed by flow cytometry using a FacsCalibur flow cytometer (Becton Dickenson, San Jose, Calif.) and CellQuest software (Becton Dickenson, San Jose, Calif.).

FIG. 3A illustrates that consumption of *Lycium Barbarum* triggered a strong transient decrease in circulating stem cells. Specifically, the X-axis shows the time course of a typical experiment after *Lycium Barbarum* ingestion, expressed as a percentage of the control level. At the time of ingestion, the proportion of circulating CD34+ cells is the same as the control. The peak decrease in circulating CD34+ cells was observed at about 1-2 hours after consumption. At this time point, the number of circulating CD34+ cells was decreased by 30% below the control value. By 4 hours after *Lycium Barbarum* ingestion, the circulating CD34+ cells had returned to the baseline value. The decrease in the number of circulating stem cells was accompanied by an increase in the expression of CXCR4 on the membrane of circulating stem cells (FIG. 6).

Therefore, *Lycium Barbarum* (or a biological component of *Lycium Barbarum*) can enhance the migration of endogenous stem cells (e.g. CD34+ cells) from the circulation to tissues. Consumption of *Lycium Barbarum* (or a biological component of *Lycium Barbarum*) triggers the migration CD34+ stem cells (e.g., see FIG. 3), thereby demonstrating the efficacy of *Lycium Barbarum* as a migration agent.

Example 3

Stem Cells Migrate following Colostrum Consumption

As in Example 2, and with reference to FIG. 3B, administration of colostrum results in stem cell migration.

Example 4

Stem Cells Migrate following Mushroom Consumption

As in Example 2, and with reference to FIG. 4, administration of a polysaccharide rich fraction of mushroom (*Cordyceps sinensis*, *Ganoderma lucidum*, *Hericium erinaceus*) results in stem cell migration.

5

Example 5

Stem Cells Migrate following Fucoidan or Spirulina Consumption

As in Example 2, administration of fucoidan from algae seaweeds such as *Chordaria cladosiphon* promotes certain beneficial results that may ultimately, albeit indirectly, assist with stem cell migration. For example, consumption of fucoidan from *Chordaria cladosiphon* resulted in a decrease in the number of circulating CD34+ HSCs (FIG. 9), suggesting an effective role in supporting stem cell migration. As in Example 2, administration of spirulina results in stem cell migration (FIG. 4B), and administration of spirulina with *Lycium Barbarum*, colostrum and mushrooms also results in stem cell migration (FIG. 7).

15

Example 6

Stem Cells Migrate following consumption of a blend of LB, colostrum, spirulina and mushroom

Compositions including the following components listed in Table 1 are provided to mammalian subjects. Administration of these compositions results in stem cell migration.

20

Table 1

	Composition 1	Composition 2	Composition 3	Composition 4
	mg/dose	mg/dose	mg/dose	mg/dose
Lycium Barbarum (Goji extract)	500	1,000	1,500	2,000
Colostrum (Fractionated)	75	150	225	300
Spirulina	75	150	225	300
Mushroom 6.255	250	500	750	1,000
Hericium erinaceus	83	166	249	332
Ganoderma Lucidum	83	166	249	332
Cordyceps Sinensis	83	166	249	332

25

Example 7

Stem Cells from Bone Marrow Populate Multiple Distant Tissues

A murine model is chosen to evaluate how a mixture of LB, colostrum and mushroom can stimulate stem cell migration into tissues, and therefore populate and repair distant tissues of the body.

Male mice are selected as bone marrow donor animals, while all recipient mice are females. Female recipients are sub-lethally irradiated prior to injection of GFP+ male bone marrow cells into their tail veins. Two groups of mice are evaluated. The first group of 20 animals are sub-lethally irradiated, injected with bone marrow, and put on normal feed. The second group of 20 animals are also sub-lethally irradiated, receive male bone marrow, and are fed a diet of normal feed plus a mixture of LB, colostrum and mushroom. Incorporation of GFP+ cells is examined in the brain, heart muscle, muscles, liver, pancreas, sections of small intestine, and lung tissue

These data document the extent to which a diet containing a mixture of LB, colostrum and mushroom promotes the homing and migration of bone marrow stem cells to various tissues.

Example 8

Increased Stem Cell Repopulation of Traumatized Tissue

A murine model is chosen to evaluate how a mixture of LB, colostrum and mushroom can stimulate stem cell migration into tissues, and therefore populate and repair distant tissues of the body.

Male mice are selected as bone marrow donor animals, while all recipient mice are females. Female recipients are sub-lethally irradiated prior to injection of GFP+ male bone marrow cells into their tail veins. Two groups of mice are evaluated. The first group of 20 animals are sub-lethally irradiated, injected with bone marrow, and put on normal feed. The second group of 20 animals are also sub-lethally irradiated, receive male bone marrow, and are fed a diet of normal feed plus a mixture of LB, colostrum and mushroom.

After bone marrow transplant and a few days prior to the initiation of the feeding trial, animals are subjected to an injury such as injection of cardiotoxin in the tibialis muscle, triggering of heart attack by ligation of coronary artery, punch of the skin, laser-induced stroke, or other injuries. The recovery of mice in both groups is monitored during 6 weeks using whole body fluorescence imaging. After 6 weeks, the animals are sacrificed and the injured tissue is analyzed to assess the extent of

tissue repair. Incorporation of GFP+ cells will also be examined in the brain, heart muscle, muscles, liver, pancreas, sections of small intestine, and lung tissue

These data document the extent to which a diet containing a mixture of LB, colostrum and mushroom promotes the homing and migration of bone marrow stem cells to injured tissues, therefore enhancing the process of tissue repair and healing.

Example 9

General Study Design for Fucoïdan as a Stem Cell Mobilization Agent

Two consumables were tested in human subjects: fucoïdan extracted from *Undaria* and a placebo. Peripheral venous blood samples were obtained from healthy human volunteers between 20 and 45 years of age upon informed consent. Blood and bone marrow samples were obtained under aseptic conditions and processed immediately. One gram of fucoïdan or placebo was given to volunteers with 4–6 oz water. Appearance of the placebo was identical to that of the fucoïdan and consisted of tan-dyed, finely ground potato flakes encapsulated in vegetable capsules.

Example 10

In Vivo Study Design

The following exclusion criteria were used: under 20 or over 65 years of age, pregnancy, severe asthma and allergies requiring daily medication, any known chronic illness or previous/current venereal disease, frequent recreational drug use, and impaired digestive function (including previous major gastrointestinal surgery). Three volunteers were scheduled on two study days one week apart. Testing was always performed at the same time of the day (8–11 a.m.) to minimize the effect of circadian fluctuations. Due to the interference from stress with the release vs. homing of other types of lymphocytes, effort was taken to minimize any physical and mental stress during testing. In addition, on each study day, volunteers were instructed to complete a questionnaire aimed at determining any exceptional stress related circumstances that might affect the person on that particular study day. Predetermined criteria for exclusion from final analysis included significant lack of sleep and severe anxiety. After completing the questionnaire, volunteers were instructed to remain quiescent for 4 h, comfortably seated in a chair. After the first hour, the baseline blood sample was drawn. Immediately after drawing the baseline

sample, a consumable was provided. Blood samples were later drawn 60, 90 and 180 min after ingestion of the consumable. At each time point, 5 ml of blood was drawn into heparin, and 2 ml blood was drawn into EDTA. The blood vials were placed on a rocking plate until use.

5

Example 11

Measurement of Stem Cell Populations using FACS Sorting

The blood drawn into EDTA was used for obtaining a complete blood count (CBC) with differential, using a Coulter counter (Micro Diff II, Beckman Coulter). All
10 CBCs were performed within an hour of drawing the sample. All CBCs were performed in triplicate. The heparinized blood was used for purification of the PBMC fraction by gradient centrifugation and processed for immunostaining and flow cytometry. The stem cell markers CD34-FITC (clone 8G12, BD BioSciences, San Jose, CA, USA) and CD133-PE (Miltenyi Biotech, Auburn, CA, USA) were used for
15 two color immunofluorescence. Staining of all samples with CD34-FITC/CD133-PE was performed in triplicate. IgG1-FITC and IgG1-PE isotype controls (BD BioSciences) were used in parallel samples. Separate, positive control samples for each donor included CD45-FITC and CD14-PE. Stained PBMC were fixed in 1% formalin and acquired by flow cytometry immediately. Files of 200,000 events were
20 collected on each triplicate sample. The percent CD34+CD133-, CD34+CD133+, and the CD34-CD133 + subsets were analyzed separately and were analyzed again after multiplying with the lymphocyte cell counts, as obtained from the average of the triplicate lymphocyte counts obtained by the CBC differential count.

25

Example 12

Increase in CD34+ HSCs circulating in peripheral blood following oral administration of fucoidan from Undaria pinnatifida.

The inventors tested oral administration of fucoidans from several different algae species for their potential to effectuate HSC mobilization in the peripheral
30 bloodstream of human subjects. Fucoidan from one species, *Undaria pinnatifida*, resulted in a significant elevation in the number of circulating CD34+ HSCs, with increases of 17%, 23% (P<0.02) and 32% ((P<0.02) occurring at 45, 90 and 180 minute measurement intervals, thereby demonstrating efficacy as a releasing agent. (FIG. 8) To the best of the inventors' knowledge, this is the most significant increase

reported in the literature and further, is a notable improvement over the previously reported 12% increase after 14 days in Irimeh et al., which also tested oral administration of fucoidan from *Undaria pinnatifida*. Importantly, Irimeh et al. reported 3 gram of fucoidan administered daily, whereas the inventors achieved improved results using a 250 mg dosage regime. This highlights an important role for applying a specific dosage when orally administering fucoidan to promote release and circulation of CD34+ HSCs. Furthermore, a lower dosage may permit longer-term patient use, such as routine daily administration, whereas higher dosages may not be compatible with repeated and/or routine use.

10

Example 13

Decrease in CD34+ HSCs circulating in peripheral blood following oral administration of fucoidan from Chordaria cladosiphon.

Extending these observations, the inventors discovered that fucoidan from several other algae species, including *Chordaria cladosiphon*, failed to elevate the circulating number of CD34+ HSCs in human subjects (FIG. 9). Despite application of several dosage regimes, including the effective 250 mg dosage of fucoidan from *Undaria pinnatifida* as described above, fucoidan from *Chordaria cladosiphon* resulted in a decrease in the number of circulating CD34+ HSCs, probably consequent to an increase in CXCR4 expression on the surface of circulating HSCs. These results reflect the complex interplay between the exact source of fucoidan and identifying an effective therapeutic dose. Consumption of 250 mg of this fucoidan from *Chordaria cladosiphon* gave an average decrease in the number of circulating stem cells (Figure 3) using the same fucoidan preparation methods and administered under the same conditions in volunteers, thereby demonstrating an effective role in supporting migration of stem cells.

These results are consistent with earlier reports that fucoidan from different sources diverge in structure-activity relationships. Fucoidan fractions from *A. nodosum* and *Pelvetia canaliculata* have been reported to possess anti-coagulant activity through the tri-sulfated disaccharide heparin-like motif involved in HSC mobilization. Particularly notable was the report that sulfation patterns correlated with their anticoagulant activities. A similar molecule from the family of galactans, 3-linked, regularly 2-O-sulfated galactan, possesses anticoagulant activity not found in a corresponding 3-linked, regularly 2-O-sulfated fucan. (Berteau and Mulloy, 2003;

30

Mourão and Pereira, 1999; Pereira et al., 2002) These reports about anti-coagulant activity and the inventors' observations about HSC mobilization clearly demonstrate that the structure-activity relationships of sulfated fucans, including fucoidan, is not the result from generic features, such as charge density from the presence or absence of certain chemical groups. Instead, biological activity depends critically on the exact structure of the polysaccharide. Necessarily, the different structural fucoidans from distinct species of algae is expected to provide a complex range of efficacies for various therapeutic applications, including HSC mobilization. As described above, this will also require establishing effective therapeutic doses, which may vary when using fucoidans from different species.

The various methods and techniques described above provide a number of ways to carry out the invention. Of course, it is to be understood that not necessarily all objectives or advantages described may be achieved in accordance with any particular embodiment described herein. Thus, for example, those skilled in the art will recognize that the methods can be performed in a manner that achieves or optimizes one advantage or group of advantages as taught herein without necessarily achieving other objectives or advantages as may be taught or suggested herein. A variety of advantageous and disadvantageous alternatives are mentioned herein. It is to be understood that some preferred embodiments specifically include one, another, or several advantageous features, while others specifically exclude one, another, or several disadvantageous features, while still others specifically mitigate a present disadvantageous feature by inclusion of one, another, or several advantageous features.

Furthermore, the skilled artisan will recognize the applicability of various features from different embodiments. Similarly, the various elements, features and steps discussed above, as well as other known equivalents for each such element, feature or step, can be mixed and matched by one of ordinary skill in this art to perform methods in accordance with principles described herein. Among the various elements, features, and steps some will be specifically included and others specifically excluded in diverse embodiments.

Although the invention has been disclosed in the context of certain embodiments and examples, it will be understood by those skilled in the art that the embodiments of the invention extend beyond the specifically disclosed embodiments

to other alternative embodiments and/or uses and modifications and equivalents thereof.

Many variations and alternative elements have been disclosed in embodiments of the present invention. Still further variations and alternate elements will be apparent to one of skill in the art. Among these variations, without limitation, are the sources of stem cell mobilization agents, the methods of preparing, isolating, or purifying stem cell mobilization agents, analogs and derivatives thereof, methods of treating various disease and/or conditions using stem cell mobilization agents, analogs and derivatives thereof, techniques and composition and use of solutions used therein, and the particular use of the products created through the teachings of the invention. Various embodiments of the invention can specifically include or exclude any of these variations or elements.

In some embodiments, the numbers expressing quantities of ingredients, properties such as concentration, reaction conditions, and so forth, used to describe and claim certain embodiments of the invention are to be understood as being modified in some instances by the term "about." Accordingly, in some embodiments, the numerical parameters set forth in the written description and attached claims are approximations that can vary depending upon the desired properties sought to be obtained by a particular embodiment. In some embodiments, the numerical parameters should be construed in light of the number of reported significant digits and by applying ordinary rounding techniques. Notwithstanding that the numerical ranges and parameters setting forth the broad scope of some embodiments of the invention are approximations, the numerical values set forth in the specific examples are reported as precisely as practicable. The numerical values presented in some embodiments of the invention may contain certain errors necessarily resulting from the standard deviation found in their respective testing measurements.

In some embodiments, the terms "a" and "an" and "the" and similar references used in the context of describing a particular embodiment of the invention (especially in the context of certain of the following claims) can be construed to cover both the singular and the plural. The recitation of ranges of values herein is merely intended to serve as a shorthand method of referring individually to each separate value falling within the range. Unless otherwise indicated herein, each individual value is incorporated into the specification as if it were individually recited herein. All methods described herein can be performed in any suitable order unless otherwise

indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (e.g. "such as") provided with respect to certain embodiments herein is intended merely to better illuminate the invention and does not pose a limitation on the scope of the invention otherwise claimed. No language
5 in the specification should be construed as indicating any non-claimed element essential to the practice of the invention.

Groupings of alternative elements or embodiments of the invention disclosed herein are not to be construed as limitations. Each group member can be referred to and claimed individually or in any combination with other members of the group or
10 other elements found herein. One or more members of a group can be included in, or deleted from, a group for reasons of convenience and/or patentability. When any such inclusion or deletion occurs, the specification is herein deemed to contain the group as modified thus fulfilling the written description of all Markush groups used in the appended claims.

15 Preferred embodiments of this invention are described herein, including the best mode known to the inventor for carrying out the invention. Variations on those preferred embodiments will become apparent to those of ordinary skill in the art upon reading the foregoing description. It is contemplated that skilled artisans can employ such variations as appropriate, and the invention can be practiced otherwise than
20 specifically described herein. Accordingly, many embodiments of this invention include all modifications and equivalents of the subject matter recited in the claims appended hereto as permitted by applicable law. Moreover, any combination of the above-described elements in all possible variations thereof is encompassed by the invention unless otherwise indicated herein or otherwise clearly contradicted by
25 context.

Furthermore, numerous references have been made to patents and printed publications throughout this specification. Each of the above cited references and printed publications are herein individually incorporated by reference in their entirety.

In closing, it is to be understood that the embodiments of the invention
30 disclosed herein are illustrative of the principles of the present invention. Other modifications that can be employed can be within the scope of the invention. Thus, by way of example, but not of limitation, alternative configurations of the present invention can be utilized in accordance with the teachings herein. Accordingly,

embodiments of the present invention are not limited to that precisely as shown and described.

REFERENCES

- 5 Abedi M., Greer D., Colvin G., Demers D., Dooner M., Harpel J., Pimentel J., Menon M., and Quesenberry P., Tissue injury in marrow transdifferentiation Blood Cells, Molecules and Diseases 2004 32, 42 – 46
- Andriole G., Mulé J., Hansen C., Linehan W., Rosenberg S., Evidence that lymphokine-activated killer cells and natural killer cells are distinct based on an analysis of congenitally immunodeficient mice. Journal of Immunology 1985 135, 2911-2913.
- 10 Adams G. and Scadden D., The hematopoietic stem cell in its place. Nature Immunology 2006 7, 333-337.
- Asahara T., Masuda H., Takahashi T., Kalka C., Pastore C., Silver M., Kearne M., Magner M., and Isner J., Bone Marrow Origin of Endothelial Progenitor Cells Responsible for Postnatal Vasculogenesis in Physiological and Pathological Neovascularization. Circulation Research 1999 85, 221-228.
- 15 Barker N, van de Wetering M, Clevers H. The intestinal stem cell. Genes and Development 2008 22,1856-64.
- Berteau O. and Mulloy B., Sulfated fucans, fresh perspectives: structures, functions, and biological properties of sulfated fucans and an overview of enzymes active toward this class of polysaccharide. Glycobiology 2003 13, 29-40.
- 20 Branski L., Gauglitz G., Herndon D., and Jeschke M., A review of gene and stem cell therapy in cutaneous wound healing. Burns, July 4. 2008.
- Burke ZD, Thowfeequ S, Peran M, Tosh D. Stem cells in the adult pancreas and liver. Biochemistry Journal 2007 404,169-78.
- 25 Dezawa M., Ishikawa H., Hoshino M., Itokazu Y., and Nabeshima Y., Potential of bone marrow stromal cells in applications for neuro-degenerative, neuro-traumatic and muscle degenerative diseases. Current Trends in Neuropharmacology 2005 3, 257-66.
- Drapeau C., Cracking the Stem Cell Code, Sutton Hart Press (Portland, OR 2010)
- 30 Fraser J., Schreiber R., Zuk P., and Hedrick M., Adult stem cell therapy for the heart. International Journal of Biochemistry & Cell Biology 2004 36, 658–666
- Frenette P. and Weiss L., Sulfated glycans induce rapid hematopoietic progenitor cell mobilization : evidence for selectin-dependent and independent mechanisms. Hemostasis, Thrombosis, and Vascular Biology 2000 96, 2460-2468.
- 35 Hidalgo, A., Sanz-Rodríguez F., Rodríguez-Fernández J., Albella B., Blaya C., Wright N., Cabañas C., Prósper F., Gutierrez-Ramos J., Teixidó J., Chemokine stromal cell-derived factor-1alpha modulates VLA-4 integrin-dependent adhesion to

fibronectin and VCAM-1 on bone marrow hematopoietic progenitor cells. *Experimental Hematology*, 2001 29, 345-55;

5 Irhimeh M., Fitton J., and Lowenthal R., Fucoidan ingestion increases the expression of CXCR4 on human CD34+ cells. *Experimental Hematology* 2007 35, 989-994.

10 Jang Y., Collector M., Baylin S., Diehl A., and Sharkis S., Hematopoietic stem cells convert into liver cells within days without fusion. *Nature Cell Biology* 2004, 6, 532-529.

Jensen, G. and Drapeau C., The use of in situ bone marrow stem cells for the treatment of various degenerative diseases. *Medical Hypotheses* 2002 59, 422-428.

15 Jensen, G., Hart A., Lue A., Drapeau C., Gupta N., Scaehffer D., and Cruickshank J. Mobilization of human CD34+CD133+ and CD34+CD133- stem cells in vivo by consumption of an extract from *Aphanizomenon flos-aquae*-related to modulation of CXCR4 expression by an L-selectin ligand? *Cardiovascular Revascularization Medicine* 2007 8, 189-202.

20 Kollet O., Spiegel A., Peled A., Petit I., Byk T., Hershkoviz R., Guetta E., Barkai G., Nagler A., Lapidot T., Rapid and efficient homing of human CD34(+)/CD38(-/low)/CXCR4(+) stem and progenitor cells to the bone marrow and spleen of NOD/SCID and NOD/SCID/B2m(null) mice. *Blood* 2001 97, 3283-91.

25 Krause D., Theise N., Collector M., Henegariu O., Hwang S., Gardner R., Neutzel S., and Sharkis S., Multi-organ, multi-lineage engraftment by a single bone marrow-derived stem cell *Cell* 2001 105, 369-377

30 Kuang S, Gillespie M., Rudnicki M. Niche regulation of muscle satellite cell self-renewal and differentiation. *Cell Stem Cell* 2008 10, 22-31.

35 McCune J., Namikawa R., Kaneshima H., Shultz L., Lieberman M., Weissman I., The SCID-hu mouse: murine model for the analysis of human hematolymphoid differentiation and function. *Science* 1998, 241, 1632-9.

40 Mourão, P., and Pereira, M., Searching for alternatives to heparin: sulfated fucans from marine invertebrates. *Trends in Cardiovascular Medicine* 1999 9, 225-232.

Pereira M., Melo F., and Mourão, P., Is there a correlation between structure and anticoagulant action of sulfated galactans and sulfated fucans? *Glycobiology* 2002 12, 573-580.

45 Revishchin A., Korochkin L., Okhotin V., Pavlova G. Neural stem cells in the mammalian brain. *International Review Cytology*. 2008 265, 55-109.

Sweeney E., Priestly G., Nakamoto B., Collins R., and Beaudet A., Mobilization of stem/progenitor cells by sulfated polysaccharides does not require

selectin presence. Proceedings of the National Academy of Sciences 2000 97, 6544-6549.

5 Sweeney E., Lortat-Jacob H., Priestly G., Nakamoto B. and Papayannopoulou T., Sulfated polysaccharides increase plasma levels of SDF-1 in monkeys and mice: involvement in mobilization of stem/progenitor cells. Blood 2008 99, 44-51.

10 Wang X, Foster M, Al-Dhalimy M, Lagasse E, Finegold M, and Grompe M. The origin and liver repopulating capacity of murine oval cells. Proceedings of the National Academy of Science 2003 Suppl. 1:11881–11888.

15 Yang L., Li S., Hatch H., Ahrens K., Cornelius J., Petersen B., Peck A. In vitro trans-differentiation of adult hepatic stem cells into pancreatic endocrine hormone-producing cells. Proceedings of the National Academy of Science 2002 99, 8078-83.

15

20

THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:

1. A method of increasing rapid stem cell mobilization in a subject, comprising:

providing at least two mobilization agents capable of increasing rapid stem cell mobilization; and

5 administering a quantity of the mobilization agents to the subject in an amount sufficient to increase rapid stem cell mobilization in the subject, wherein the at least two mobilisation agents comprise:

a fucoidan; and

10 one or more of the following components selected from the group consisting of: *Lycium barbarum* or extracts thereof, colostrum or extracts thereof, spirulina or extracts thereof, *Hericium erinaceus* or extracts thereof, *Ganoderma lucidum* or extracts thereof, and *Cordyceps sinensis* or extracts thereof, wherein the rapid stem cell mobilisation occurs in a period of less than 24 hours after administration.

2. The method of claim 1, wherein the quantity of the fucoidan is 50-250 mg.

15 3. The method of claim 1, wherein the quantity of the fucoidan is 250 mg.

4. The method of any one of the preceding claims, wherein administering the quantity comprises oral administration.

5. The method of claim 4, wherein the oral administration comprises use of a capsule or a pill.

20 6. A method of increasing rapid stem cell mobilization in a subject, comprising:

providing 50-250 mg of a fucoidan capable of increasing rapid stem cell mobilization; and

25 one or more of the following components selected from the group consisting of: *Lycium barbarum* or extracts thereof, colostrum or extracts thereof, spirulina or extracts thereof, fucoidan, *Hericium erinaceus* or extracts thereof, *Ganoderma lucidum* or extracts thereof, and/or *Cordyceps sinensis* or extracts thereof; and

orally administering the fucoidan to a subject once a day.

7. A method of increasing rapid stem cell mobilization in a subject, comprising:

providing 250 mg of a fucoidan capable of increasing rapid stem cell mobilization; and

5 one or more of the following components selected from the group consisting of: *Lycium barbarum* or extracts thereof, colostrum or extracts thereof, spirulina or extracts thereof, fucoidan, *Hericium erinaceus* or extracts thereof, *Ganoderma lucidum* or extracts thereof, and/or *Cordyceps sinensis* or extracts thereof; and

orally administering the fucoidan to a subject once a day.

10 8. The method of any one of the preceding claims, wherein the stem cell is a bone marrow-derived stem cell (BMSC).

9. The method of any one of the preceding claims, wherein the stem cell is a hematopoietic stem cell (HSC).

15 10. The method of any one of the preceding claims, wherein the fucoidan is extracted from *Undaria pinnatifida*.

11. A pharmaceutical composition when used to increase rapid stem cell mobilisation in a subject, the composition comprising:

less than 300 mg of fucoidan; and

20 one or more of the following components selected from the group consisting of: *Lycium barbarum* or extracts thereof, colostrum or extracts thereof, spirulina or extracts thereof, *Hericium erinaceus* or extracts thereof, *Ganoderma lucidum* or extracts thereof, and *Cordyceps sinensis* or extracts thereof; and


a pharmaceutically acceptable carrier,

25 wherein the rapid stem cell mobilisation occurs in a period of less than 24 hours after administration of the composition.

12. The pharmaceutical composition of claim 11, wherein the quantity of *Lycium barbarum* or extracts thereof, comprises 500-2000 mg in a single dose.
13. The pharmaceutical composition of claim 11 or 12, wherein the quantity of colostrum or extracts thereof, comprises 75-300 mg in a single dose.
- 5 14. The pharmaceutical composition of and one of claims 11 to 13, wherein the quantity of spirulina or extracts thereof, comprises 75-300 mg in a single dose.
- 10 15. The pharmaceutical composition of any one of claims 11 to 14, wherein the quantity of *Hericium erinaceus* or extracts thereof, *Ganoderma lucidum* or extracts thereof, and/or *Cordyceps sinensis* or extracts thereof comprises 83-1000 mg in a single dose.
16. The pharmaceutical composition of any one of claims 11 to 15, wherein the quantity of fucoidan is 50 – 250 mg in a single dose.
17. The pharmaceutical composition of any one of claims 11 to 15, wherein the quantity of fucoidan is 250 mg in a single dose.
- 15 18. A method according to any one of claims 1, 6 or 7, substantially as hereinbefore described.
19. A pharmaceutical composition according to claim 11, substantially as hereinbefore described.

Figure 1.

A.



B.




Figure 1.

C.




Figure 2.





Figure 3.

A.



B.




Figure 4.





Figure 5.

A.



B.





Figure 5.

C.






Figure 7.




Figure 8. Number of CD34+ cells




Figure 9. Number of CD34+ cells (Fuc)

